P. Rossing

New England Journal of Medicine · 2015–2024

A researcher in the Science corpus: 16 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from P. Rossing's perspective

Ordered by how strongly the researchers P. Rossing trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
  2. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (New England Journal of Medicine)
  3. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes… (Diabetologia)
  4. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. (The Lancet)
  5. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes (New England Journal of Medicine)
  6. Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni… (Circulation)
  7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. (The Lancet Diabetes and Endocrinology)
  8. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of… (Diabetologia)
  9. Telmisartan, ramipril, or both in patients at high risk for vascular events. (New England Journal of Medicine)
  10. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Their papers